Read full announcement on Path BioAnalytics site
Path BioAnalytics Inc. (PBA), a precision medicine company focused on the discovery and development of new treatments for respiratory disease, today announced it has licensed rights to cavosonstat from Laurel Therapeutics, a global clinical-stage biopharmaceutical company headquartered in Hangzhou China. PBA will use its proprietary technology to identify subpopulations of patients in which the drug candidate is effective, and if successful, will file an Investigational New Drug (IND) application to conduct clinical development. Under the terms of the license, PBA has exclusive rights outside Asia to develop cavosonstat for cystic fibrosis.
“At PBA, we have developed an innovative organoid platform using primary cells to support drug development for targeted patient populations. We are excited to be able to apply this technology to cavosonstat and advance it through our pipeline and into the clinic for cystic fibrosis,” said John Mellnik, Ph.D., CEO of PBA. “This program advances our strategy of developing novel candidates with proven clinical safety and identifying subpopulations in which they will be most effective. We believe that we have found an excellent partner in Laurel Therapeutics, a company that shares our focus on addressing the high burden of respiratory diseases world-wide.”
Cystic fibrosis (CF) is a fatal genetic disease affecting more than 70,000 individuals world-wide. CF is caused by genetic mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which encodes the CFTR protein. Over 2,000 mutations in the CFTR gene with varying degrees of clinical relevance have been identified. CF impacts multiple organ systems in the body; however, CF’s impact on the lungs, where it causes frequent lung infections and shortness of breath, is the primary driver of mortality. There is no cure for CF.
| UNC-CH